KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Halozyme Therapeutics (HALO) Shares Outstanding (Diluted Average): 2015-2024

Historic Shares Outstanding (Diluted Average) for Halozyme Therapeutics (HALO) over the last 10 years, with Dec 2024 value amounting to $129.4 million.

  • Halozyme Therapeutics' Shares Outstanding (Diluted Average) fell 4.37% to $124.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $124.4 million, marking a year-over-year decrease of 4.37%. This contributed to the annual value of $129.4 million for FY2024, which is 3.56% down from last year.
  • Halozyme Therapeutics' Shares Outstanding (Diluted Average) amounted to $129.4 million in FY2024, which was down 3.56% from $134.2 million recorded in FY2023.
  • In the past 5 years, Halozyme Therapeutics' Shares Outstanding (Diluted Average) ranged from a high of $146.8 million in FY2021 and a low of $129.4 million during FY2024.
  • Moreover, its 3-year median value for Shares Outstanding (Diluted Average) was $134.2 million (2023), whereas its average is $134.7 million.
  • In the last 5 years, Halozyme Therapeutics' Shares Outstanding (Diluted Average) climbed by 3.77% in 2021 and then decreased by 4.56% in 2023.
  • Yearly analysis of 5 years shows Halozyme Therapeutics' Shares Outstanding (Diluted Average) stood at $141.5 million in 2020, then rose by 3.77% to $146.8 million in 2021, then dropped by 4.22% to $140.6 million in 2022, then dropped by 4.56% to $134.2 million in 2023, then fell by 3.56% to $129.4 million in 2024.